Funds Raised: David Domzalski Discusses the Closing of VYNE Therapeutics’ Private Placement

Shots:  David Domzalski, President & Chief Executive Officer at VYNE Therapeutics, in an invigorating conversation with PharmaShots  The PIPE transaction generated $88M ensuring a steady cash flow through the end of 2025 and multiple anticipated clinical catalysts across VYNE’s BET inhibitor platform  David believes the financing will be instrumental in the advancement of VYN201, into…